Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: A comparison of population-level case ascertainment methods

Parkinsonism and Related Disorders

Volumn 17, Issue 6, 2011, Pages 464-469

  Harris, M Anne ^a   Koehoorn, Mieke ^b   Teschke, Kay ^b  

^a Occupational Cancer Research Centre   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Case ascertainment; Data collection; Epidemiologic methods; Levodopa; Parkinson's disease

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; CASE FINDING; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH SURVEY; HOSPITAL BILLING; HOSPITAL DISCHARGE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SELF REPORT; SENSITIVITY AND SPECIFICITY; SEX RATIO;

ANTIPARKINSON AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEVODOPA; PARKINSON DISEASE; PATIENT SELECTION; PREVALENCE;

EID: 79959333425     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.04.007     Document Type: Article

References (32)

1. Fall P.A., Axelson O., Fredriksson M., Hansson G., Lindvall B., Olsson J.E., et al. Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community. J Clin Epidemiol 1996, 49:637-641.
2. Chio A., Magnani C., Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998, 13:400-405.
3. Lai B.C.L., Schulzer M., Marion S., Teschke K., Tsui J.K.C. The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat Disord 2003, 9:233-238.
4. Hernan M.A., Zhang S.M., Rueda-deCastro A.M., Colditz G.A., Speizer F.E., Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. Ann Neurol 2001, 50:780-786.
5. Schrag A., Ben-Shlomo Y., Quinn N.P. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ (Clin Res Ed) 2000, 321:21-22.
6. Chan D.K., Cordato D., Karr M., Ong B., Lei H., Liu J., et al. Prevalence of Parkinson's disease in Sydney. Acta Neurol Scand 2005, 111:7-11.
7. Glik A., Masarwa M., Abuful A., Deeb A., Strugatsky R., Farrer L.A., et al. Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Mov Disord 2009, 24:119-122.
8. Li S.C., Schoenberg B.S., Wang C.C., Cheng X.M., Rui D.Y., Bolis C.L., et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 1985, 42:655-657.
9. Brandt-Christensen M., Kvist K., Nilsson F.M., Andersen P.K., Kessing L.V. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 2006, 21:1221-1225.
10. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56:33-39.
11. Statistics Canada Definitions, data sources and methods 2007, Canadian Community Health Survey, http://www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3226&SurvVer=0&InstaId=15282&InstaVer=3&SDDS=3226&lang=en&db=imdb&adm=8&dis=2 [accessed 19.06.2010].
12. Statistics Canada - Health Statistics Division. Quality measures, Canadian Community Health Survey (CCHS) (Survey numbers 3226 and 5015) 2003. URL: [accessed 14.08.2010]. http://www.statcan.gc.ca/imdb-bmdi/document/3226_D9_T9_V1-eng.pdf.
13. Morgan SG, Cunningham C, Hanley G, Mooney D. The British Columbia Rx Atlas. 2nd ed. University of British Columbia Centre for Health Services and Policy Research. 2009. URL: [accessed 26.04.2011]. http://www.chspr.ubc.ca/rxatlas/bc.
14. Agresti A., Coull B.A. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998, 52:119-126.
15. Trifiro G., Savica R., Morgante L., Vanacore N., Tari M., Moretti S., et al. Prescribing pattern of anti-Parkinson drugs in Southern Italy: cross-sectional analysis in the years 2003-2005. Parkinsonism Relat Disord 2008, 14:420-425.
16. Vanacore N., Bianchi C., Da Cas R., Rossi M. Use of antiparkinsonian drugs in the Umbria Region. Neurol Sci 2003, 24:221-222.
17. Tan E.K., Yeo A.P., Tan V., Pavanni R., Wong M.C. Prescribing pattern in Parkinson's disease: are cost and efficacy overriding factors?. Int J Clin Pract 2005, 59:511-514.
18. Snow B., Wiens M., Hertzman C., Calne D. A community survey of Parkinson's disease. CMAJ 1989, 141:418-422.
19. Gambassi G., Landi F., Peng L., Brostrup-Jensen C., Calore K., Hiris J., et al. Validity of diagnostic and drug data in standardized nursing home resident assessments: potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Med Care 1998, 36:167-179.
20. Pramstaller P.P., Falk M., Schoenhuber R., Poewe W. Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). J Neurol 1999, 246:79-86.
21. Rocca W.A., Maraganore D.M., McDonnell S.K., Schaid D.J. Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol 1998, 51:517-523.
22. de Lau L.M., Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 2006, 5:525-535.
23. Thomas K., Watson C.B. Restless legs syndrome in women: a review. J Womens Health (Larchmt) 2008, 17:859-868.
24. Conti C.F., de Oliveira M.M., Andriolo R.B., Saconato H., Atallah A.N., Valbuza J.S., et al. Levodopa for idiopathic restless legs syndrome: evidence-based review. Mov Disord 2007, 22:1943-1951.
25. Cotter P.E., O'Keeffe S.T. Restless leg syndrome: is it a real problem?. Ther Clin Risk Manag 2006, 2:465-475.
26. Bayard M., Avonda T., Wadzinski J. Restless legs syndrome. Am Fam Phys 2008, 78:235-240.
27. Ferini-Strambi L. Treatment options for restless legs syndrome. Expert Opin Pharmacother 2009, 10:545-554.
28. Askmark H., Antonov K., Aquilonius S.M. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption-a nation-wide perspective in Sweden. Parkinsonism Relat Disord 2003, 9:271-276.
29. Harris M.A. Too soon for dopaminergics in the management of restless legs syndrome in children. Sleep Med Rev 2009, 13:299-300. [author reply 1-2].
30. Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003, 18:467-486.
31. Finkelstein M.M., Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 2007, 104:420-432.
32. De Vera M., Rahman M.M., Rankin J., Kopec J., Gao X., Choi H. Gout and the risk of Parkinson's disease: a cohort study. Arthritis Rheum 2008, 59:1549-1554.